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Tumor cell-macrophage interactions change as the tumor progresses, and the generation
of nitric oxide (NO) by the inducible nitric oxide synthase (iNOS) plays a major role in
this interplay. In early stages, macrophages employ their killing mechanisms, particularly
the generation of high concentrations of NO and its derivative reactive nitrogen species
(RNS) to initiate tumor cell apoptosis and destroy emerging transformed cells. If the
tumor escapes the immune system and grows, macrophages that infiltrate it are
reprogramed in situ by the tumor microenvironment. Low oxygen tensions (hypoxia)
and immunosuppressive cytokines inhibit iNOS activity and lead to production of low
amounts of NO/RNS, which are pro-angiogenic and support tumor growth and metastasis
by inducing growth factors (e.g., VEGF) and matrix metalloproteinases (MMPs). We
review here the different roles of NO/RNS in tumor progression and inhibition, and the
mechanisms that regulate iNOS expression and NO production, highlighting the role
of different subtypes of macrophages and the microenvironment. We finally claim that
some tumor cells may become resistant to macrophage-induced death by increasing their
expression of microRNA-146a (miR-146a), which leads to inhibition of iNOS translation.
This implies that some cooperation between tumor cells and macrophages is required
to induce tumor cell death, and that tumor cells may control their fate. Thus, in order
to induce susceptibility of tumors cells to macrophage-induced death, we suggest a
new therapeutic approach that couples manipulation of miR-146a levels in tumors with
macrophage therapy, which relies on ex vivo stimulation of macrophages and their
re-introduction to tumors.
Keywords: inducible nitric oxide synthase (iNOS), tumor cells, macrophage activation, apoptosis, angiogenesis,
miR-146a, macrophage-induced death, macrophage therapy
IMMUNOEDITING: INTERPLAY BETWEENMACROPHAGES
AND TUMOR CELLS
Tumors arise when tissue cells accumulate genetic alter-
ations/mutations that disrupt the tightly controlled cell growth
and division systems (Hanahan and Weinberg, 2011), leading
to uncontrolled proliferation of these cells and increased tumor
mass. After overcoming intrinsic tumor-suppressor mechanisms
(Vesely et al., 2011), the cells have to evade the immune sys-
tem. In fact, most of the time the immune system succeeds in
eliminating those aberrant cells, in a process once known as
immunosurveilence (Dunn et al., 2004; Vesely et al., 2011). To
better describe the complex interactions between tumor cells and
the immune system, the term “immnoediting” has been coined
(Dunn et al., 2004; Bui and Schreiber, 2007; Reiman et al., 2007;
Schreiber et al., 2011) and consists of three stages; In the first stage
(the elimination stage, previously known as immunosurveilence)
immune cells destroy emerging transformed cells and prevent
their development into a tumor. If this process is unsuccessful,
there is a transition period to the second phase (equilibrium),
where the immune system is able to contain but not eliminate the
tumor. During equilibrium, the tumor cells are under constant
immune pressure that eliminates many of the original variants but
additional mutations may allow for new variants to be generated.
Eventually, some variants may escape from the immune pressure
triggering the third phase (escape), and becoming free to grow in
an immunologically unrestricted manner. This sequence of events
means that there is a constant and dynamic interplay between
the tumor cells and the stroma immune cells, which continuously
changes according to the shift in conditions. Among the immune
cells, macrophages are the most prominent, as they infiltrate deep
into the low oxygen tension (hypoxic) regions of the tumor and
accumulate there, so that in some cases they canmake up as much
as 50% of the tumor mass (Murdoch et al., 2004; Mantovani et al.,
2008).
Generally, macrophages are cells known to infiltrate tissues in
order to combat and eradicate invading pathogens and tumor
cells. Actually, they have additional tasks, including patrolling
their surroundings and maintaining homeostasis, orchestrating
tissue healing and repair and resolving inflammation. It is obvious
that such opposing functions cannot be simultaneously per-
formed by the same macrophage, and therefore, it was suggested
that macrophages can be differentially activated depending on
the signals they receive from their immediate microenviron-
ment. Thus, macrophages display enormous plasticity (Stout and
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Suttles, 2004; Stout et al., 2009), and can shift from one activa-
tion mode to another, unlike lymphocytes that remain committed
to only one kind of activation. This concept has been extensively
reviewed before (Mosser and Edwards, 2008; Murdoch et al.,
2008; Martinez et al., 2009; Gordon andMartinez, 2010; Qian and
Pollard, 2010) and will be only briefly mentioned here.
In recent yearsmany studies have shown that during the escape
phase macrophages become supportive and even critical to tumor
progression, growth and metastasis, as they produce growth fac-
tors, cytokines and chemokines which are necessary for these
processes. In order to escape immune killing, tumor cells acti-
vate several mechanisms to control the immune response, which
include acquiring defects in the antigen processing and presenta-
tion pathways to facilitate evasion from adaptive immune recog-
nition (Rabinovich et al., 2007), secretion of immunosuppressive
mediators (e.g., TGFβ, IL-10, IL-13, PGE2), and recruitment of
regulatory immune cells (Bui and Schreiber, 2007; Rabinovich
et al., 2007).
In this review we focus on the interplay between tumor cells
and macrophages during different stages of tumor development,
as manifested by the complex roles of a single molecule—
inducible nitric oxide synthase (iNOS) and its product nitric
oxide (NO). We review the conditions that regulate its expression
and activity in different cell types and in changing microenviron-
ments, and explore the significance of these differences. Finally,
we describe possible future approaches that explore whether these
interactions can be modulated in order to manipulate expres-
sion of iNOS or its activity, and to effectively enhance tumor
eradication.
NO PRODUCTION IN DIFFERENT TYPES OF MACROPHAGE
ACTIVATION
Generally, three types of macrophage activation can be described.
Classically activated or M1 macrophages are activated by ligands
of toll-like receptors (TLRs) and pro-inflammatory cytokines
(e.g., interferon γ—IFNγ, tumor necrosis factor α—TNFα, inter-
leukin 1β—IL-1β), they activate the Th1 immune response and
secrete high amounts of pro-inflammatory mediators that kill the
invading pathogens or tumor cells, such as the cytotoxic TNFα
and NO. In fact, the high expression of the iNOS that produces
NO is the hallmark of these macrophages (Mosser, 2003; Mosser
and Zhang, 2008). Alternatively or M2 activated macrophages are
activated by and secrete anti-inflammatory mediators (e.g., IL-10,
IL-13, tumor growth factor β—TGFβ, and prostaglandin E2—
PGE2), which together generate a microenvironment that sup-
presses the activity ofM1macrophages and Th1 lymphocytes. M2
macrophages are involved mainly in homeostasis, tissue remodel-
ing and wound healing, as they remove cellular debris, support
phagocytosis (by expressing scavenger receptors. the mannose
receptor CD206), and deposit extracellular matrix (ECM) pro-
teins (e.g., fibronectin). M2 macrophages express high levels of
arginase-I, which produces ornithine, the precursor of collagen.
Arginase-I also competes with iNOS for their common sub-
strate L-arginine, and prevents NO production (Martinez et al.,
2009; Gordon and Martinez, 2010). Regulatory macrophages, a
third type of activation, can be activated by TLR and immune
complexes, by anti-inflammatory cytokines or mediators (e.g.,
adenosine), or by phagocytosis of apoptotic cells (Mosser, 2003;
Mosser and Edwards, 2008). While several subtypes of regu-
latory activations have been identified, all types inhibit pro-
inflammatory reactions, partly by secreting anti-inflammatory
cytokines (e.g., IL-10, TGFβ). As macrophages exhibit great plas-
ticity, they may exhibit additional types of activation within the
range defined by these three main types to yield many different
sub-populations with different roles and functions (Mosser and
Edwards, 2008).
Three main macrophage subsets have been identified within
the tumor mass and can be localized in different niches of the
tumor (Lewis and Pollard, 2006). Tumor-associated macrophages
(TAMs) support tumor progression and metastasis, as they
secrete pro-angiogenic growth factors (e.g., vascular endothe-
lial cell growth factor—VEGF), and matrix metalloproteinases
(MMPs). TAMs infiltrate deep into the tumor and are found
in perinecrotic and hypoxic areas. In addition to the secretion
of many pro-angiogenic factors (e.g., FGF2, IL-8, PDGF, VEGF,
MMP-7, and MMP-12), TAMs also use several mechanisms to
render M1 macrophages as well as CD4+ and CD8+ T cells
non-responsive to tumor-specific antigens, including secretion
of immunosuppressive mediators (e.g., IL-10) and depletion of
L-arginine by the activity of arginase-I (Coffelt et al., 2009).
Moreover, TAMs are necessary for metastasis, and their abil-
ity to secrete EGF together with the ability of tumor cells to
secrete M-CSF/CSF-1 stimulate mutual migration in both cell
types (Wyckoff et al., 2004; Condeelis and Pollard, 2006; Coffelt
et al., 2009; Hernandez et al., 2009).
Tie2-expressing monocytes (TEMs), that unlike TAMs reside
very close to blood vessels (Venneri et al., 2007), are similar to
TAMs in their support for tumor progression and metastasis
via pro-angiogenic growth factors such as VEGF and MMPs. In
fact, TEMs are essential for tumor progression, as their deple-
tion markedly inhibits tumor angiogenesis (De Palma et al., 2005;
Venneri et al., 2007). In addition, TEMs are potent immunosup-
pressive cells, as they can secrete high levels of IL-10, suppress T
cell proliferation and promote the expansion of regulatory T cells
(Treg) (Coffelt et al., 2011).
In tumor-bearing mice and humans, expanded populations
of myeloid-derived suppressor cells (MDSCs) are found within
the tumors, spleen and bone marrow in proportion to the
tumor size. MDSCs are a mixture of immature granulocytic and
monocytic cells, and monocytic MDSCs belong to the regula-
tory macrophages. MDSCs are triggered by a combination of
IFNγ and IL-13, and secrete IFNγ, IL-13, IL-10, and TGFβ,
which help them suppress Th1 cell-mediated immune response,
induce regulatory T cells and inhibit M1 macrophages (Bronte,
2009; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and
Sinha, 2009). Production of NO and peroxynitrite helpMDSCs to
nitrate the TCR and CD8 molecules on cytotoxic T cells, inhibit-
ing the ability of the latter to bind to MHC class I molecules and
rendering them non-responsive (Nagaraj et al., 2007; Nagaraj and
Gabrilovich, 2008).
TAMs, TEMs, and MDSCs express similar activation mark-
ers, which place them between regulatory macrophages and
M2 macrophages (De Palma et al., 2007; Mosser and Edwards,
2008; Murdoch et al., 2008). More accurately, these macrophages
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exhibit a mixed expression profile, of both M1 and M2 mark-
ers. In this respect, TEMs are considered more M2-skewed than
TAMs, as they express more arginase-I but less iNOS (Pucci et al.,
2009), whereas MDSCs express both arginase-I and iNOS (Corzo
et al., 2010). It is possible that these subsets represent different
linages that develop separately (Pucci et al., 2009), or they may
gradually progress from one to the other, as they migrate from
the blood vessels into the perinecrotic areas and continue to be
polarized or reprogrammed by the local tumoral microenviron-
ment that consists of a gradient of cytokines and hypoxia, and by
the interactions with the tumor cells.
THE MULTIPLE BIOLOGICAL ROLES OF NO IN TUMORS
NO is a small, short-lived, lipophilic gas molecule, which can
easily cross membranes, and rapidly reacts with oxygen or super-
oxide to generate the derivatives that exert its biological activity.
NO has been shown to both promote and inhibit tumor growth
and metastasis. Although first recognized as a cytotoxic molecule
that serves as a major killing mechanism of macrophages dur-
ing pathogen infection or tumor cell killing, it also functions as
a regulator of wound healing, tissue repair and suppression of the
immune response-properties required to promote tumor growth.
In fact, the different levels of iNOS expression in TAMs, TEMs,
and MDSCs suggest multiple roles.
NO is produced by three isoforms of nitric oxide synthase
(NOS) that convert L-arginine to L-citrulline. The endothelial
(eNOS/NOS3) and neuronal (nNOS/NOS1) isoforms produce
low amounts of NO (in the pM-nM range), and produce only
a small fraction of the total NO in tumors. The bulk of NO
in tumors is produced by the high output inducible isoform
(iNOS/NOS2), which is strongly induced in macrophages and
in tumor cells, and produces high concentrations of NO (in the
μM range) (Xie and Nathan, 1994). It is important to note that
unlike other inflammatory mediators that need to be enzymat-
ically modulated or degraded, NO can chemically and directly
react with other molecules (e.g., oxygen, superoxide) to produce
multiple derivatives. Some of these derivatives are relatively sta-
ble (e.g., nitrites, hydroxylamine), and some are reactive nitrogen
species (RNS) (e.g., peroxynitrite, nitrogen dioxide, nitroxyl) that
are also biologically active (Donzelli et al., 2006). More details
on the complex NO chemistry can be found elsewhere (Lechner
et al., 2005; Wink et al., 2011). Since it is very difficult to separate
between the effects of NO and its active derivatives, we will refer
to them collectively as NO/RNS.
Depending on their concentrations, NO/RNS react with DNA,
proteins and lipids and can act either as a signaling molecule that
initiates signaling pathways or as a molecule that causes damage.
Depending on the balance with other ROS, especially superox-
ide, NO/RNS may deaminate the DNA bases guanine, cytosine
and adenine, causing DNA breaks and mutations, or it can
affect proteins in one of four ways: (1) oxidation of metal pros-
thetic groups (heme or non-heme); (2) nitration, the covalent
attachment of a nitro group (Tyr–NO2) to tyrosine and tryp-
tophan residues; (3) S-nitrosylation of thiol and amine groups,
which covalently attaches NO to form a weak and reversible
S-nitrosothiol (S-NO) bond; (4) oxidation of thiol groups in cys-
teine and methionine residues, that yield intramolecular disulfide
bonds (-S-S-), cysteine sulfenic acid (R-S-OH), sulfinic acid (R-
SO2H) or sulfonic acids (R-SO3H) (Lala and Chakraborty, 2001;
Leon et al., 2008). These post-translational modifications can
potentially activate or inhibit target proteins, with different bio-
logical consequences. The final biological outcome depends on
the NO concentrations produced, on the cellular redox state and
bioavailability of other ROS, on the cellular location of produc-
tion, on the distance of the impacted proteins from the generated
NO, and on the cell type (Leon et al., 2008). Research conducted
with NO donors revealed threshold concentrations of NO/RNS
that are needed to activate specific pathways. For example, 50 nM
of NO were sufficient to phosphorylate ERK, 100 nM stabi-
lized HIF-1α and activated the Akt pathway, more than 300 nM
were required to cause DNA damage and induce p53 and 1μM
was considered nitrosative stress (Wink et al., 2011). In tumors,
NO was described to have both pro- and anti-tumoral effects,
depending first and foremost on its concentrations (summarized
schematically in Figure 1). As these aspects have been extensively
reviewed elsewhere (Lala and Chakraborty, 2001; Lechner et al.,
2005; Lancaster and Xie, 2006; Weigert and Brune, 2008), we will
only briefly mention these here.
TUMOR INHIBITING ACTIVITIES
In general, high concentrations of NO/RNS can arrest cell cycle
(cytostatic effect) or induce death, whereas low concentrations
may protect cells from death. In fact, generation of high levels of
NO/RNS is a very effective tool to induce death, andmacrophages
use it as a major weapon in their arsenal against invading
pathogens and tumor cells (Weigert and Brune, 2008). High lev-
els of NO/RNS post-transnationally modify death-related target
proteins, and could mediate inhibition of cellular respiration in
target cells, leading to their cell cycle arrest.
Modification of death receptors of the TNFα superfamily (e.g.,
Fas, TRAIL, and TNFRI, DR4, and DR5), or of mitochondrial tar-
gets that affect the mitochondrial respiratory chain and its outer
membrane permeability leading to the release of cytochrome c
and initiation of apoptosis, are the two main pathways lead-
ing to cell death [extensively reviewed in Lechner et al. (2005),
Jeannin et al. (2008), Leon et al. (2008)]. Thus, S-nitrosylation
of the YY1 transcription factor alleviates its suppression on the
Fas promoter, resulting in increased apoptosis, and NO-donors
enhance apoptosis by increasing the expression of TNFα recep-
tors. NO/RNS can bind to the heme-copper center of the reduced
form of cytochrome c oxidase, compete for the binding of oxy-
gen, and cause inhibition of the mitochondrial respiratory chain
and finally increased mitochondrial membrane permeability and
release of cytochrome c (Brune, 2003; Jeannin et al., 2008).
Additional mechanisms may support initiation of apoptosis.
For example, NO/RNS may enhance phosphorylation of ser-
ine residue 15 of the wild type p53, causing its activation and
increased nuclear retention, thereby initiating apoptosis (Brune,
2003; Jeannin et al., 2008), as well as transiently and reversibly
down-regulating mdm2, thus contributing to p53 activation
(Brune, 2003). NO/RNS in amounts that favor generation of per-
oxynitrite and DNA damage, lead to accumulation of nitrated
p53, improve its DNA binding and cause apoptosis (Leon et al.,
2008). Another example is the S-nitrosylation of the p50 subunit
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FIGURE 1 | Effect of Macrophage NO on tumor carcinogenesis,
apoptosis and angiogenesis. M1-activated macrophages that produce
high amounts of NO/RNS help carcinogenesis by increasing DNA
breaks and mutations, arresting the DNA repair system and inducing
oncogenes or inactivating tumor suppressor genes. High levels of
NO/RNS may also drive apoptosis of established tumor cells, by
modifying death receptors an increasing their expression, by inhibiting
NF-kB and by enhancing cytochrome c release from the mitochondria.
Low levels of NO/RNS produced in different subsets of M2-activated
macrophages, and are reduced due to the effects of inhibitory
microenvironmental factors, such as hypoxia. Hypoxia and NO/RNS
stabilize the HIF family of transcription factors, and activate the MAPK
ERK1/2 and the PI3K pathways, thus inducing the expression of
pro-angiogenic factors, as described in the text. Purple arrows indicate
post-translation modification (e.g., S-nitrosylation) of proteins, black
arrows indicate activation of a protein/process, dashed arrows indicate
a multi-step process, thin dashed arrows indicate the inhibitory effects
of microenvironmental factors on NO/RNS production.
of NF-κB on cysteine residue 62 that inhibits its DNA binding
activity and reduces NF-κB activity, which is generally considered
an anti-apoptotic factor.
TUMOR PROMOTING ACTIVITIES
When discussing the tumor-promoting activities of NO/RNS, it is
necessary to distinguish between carcinogenic activities that pro-
mote tumor generation, and activities that support a pre-exiting
tumor at the stage of escape from the immune system.
Carcinogenesis
Chronic inflammation is linked to tumors and is recognized as
a predisposing factor for malignant transformation of tissue cells
(Kundu and Surh, 2008). In particular, the high amounts of ROS
and RNS that are generated by recruited macrophages and neu-
trophils, as part of their killing mechanisms, play an important
role. Since NO/RNS are lipophilic and can easily cross mem-
branes, tissue cell DNA is exposed to the high concentrations,
which may oxidize and/or deaminate the DNA bases, especially
during transcription or replication where single strand DNA is
more prevalently found. This may result in DNA breaks, DNA
base modifications or DNA cross-links, which cause mutations,
and may activate oncogenes or deactivate tumor suppressor genes
(Lechner et al., 2005; Kundu and Surh, 2008). In addition,
NO/RNS-driven protein modifications such as S-nitrosylation or
nitration may inhibit proteins belonging to the DNA repair sys-
tems and hamper attempts to correct mutations. Thus, NO/RNS
drive genomic instability.
In addition, there are many isolated examples for NO-driven
protein modifications that further explain the carcinogenic effects
of NO/RNS. For example, a negative feedback loop exists between
iNOS and p53. NO activates wild-type p53, which is itself a neg-
ative regulator of iNOS that binds to its promoter and inhibits
iNOS transcription. However, in tumors, p53 is often mutated
and cannot inhibit iNOS expression (Lechner et al., 2005). Thus,
in a model of chronic inflammation in p53 knockout mice,
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increased NO production accelerated spontaneous tumor devel-
opment, compared to the control mice (Hussain et al., 2008).
NO-driven hyperphosphorylation of retinoblastoma (Rb) inac-
tivated this tumor suppressor gene in a model of mouse colitis,
(Ying et al., 2007). High amounts of NO induced the expression
of c-Myc in a breast cancer cell line (Glynn et al., 2010), and acti-
vated EGFR and Src in estrogen receptor negative breast cancer
patients through S-nitrosylation (Switzer et al., 2012). All of these
examples provide a link between chronic inflammation, sustained
production of NO/RNS and carcinogenesis.
In the escape phase
When tumor cells are already at the escape phase, they employ
many pathways to maintain low levels of NO/RNS, as low
amounts of NO/RNS are actually beneficial to the tumor cells.
Anti-inflammatory mediators in the tumor microenvironment
(e.g., TGFβ) reduce transcription of iNOS mRNA and effec-
tively lower production of NO. Arginase-I that is highly expressed
by the TAMs and MDSCs depletes L-arginine and leaves insuf-
ficient amounts of this common substrate for iNOS activity
(Heller, 2008; Wink et al., 2011). In addition, if NO is secreted
from TAMs, it is likely to be captured by red blood cells,
where it S-nitrosylates their glutathione and hemoglobin, result-
ing in additional decrease in NO/RNS concentrations (Heller,
2008). Moreover, although hypoxia increases the expression of
the iNOS mRNA and protein through the transcription fac-
tors HIF-1α and NF-κB, the hypoxic microenvironment actu-
ally inactivates the enzyme activity (Melillo et al., 1996), either
because of the lack in the enzyme substrate or due to disrup-
tion of its protein–protein interactions with α-actinin-4 (Daniliuc
et al., 2003). Collectively, these mechanisms ensure that only
low amounts of NO/RNS are generated within the tumoral
microenvironment.
Low amounts of NO/RNS are anti-apoptotic and beneficial
for tumor cells. S-nitrosylation of caspases, especially caspase-3,
inhibits the enzymes, and blocks apoptosis (Leon et al., 2008).
S-nitrosylation of the FLIP adaptor protein prevents its Fas-
induced ubiquitination and degradation and enables it to exert its
anti-apoptotic activity (Iyer et al., 2008). Similarly, S-nitrosylation
of Bcl2 also protected this protein from ubiquitination and degra-
dation (Iyer et al., 2008). Thus, low amounts of NO/RNS which
activate S-nitrosylation of proteins may be a general mechanism
to prevent degradation of anti-apoptotic proteins and protect cells
from death.
The role of NO in Angiogenesis. Angiogenesis, the process in
which vascular endothelial cells proliferate and reorganize to form
new vessels sprouting from pre-existing blood vessels, is essen-
tial for the growth of most primary tumors and their subsequent
metastasis. Hypoxic core regions in tumors, which lack oxygen
and nutrients, initiate the process of angiogenesis to generate
growth of new blood vessels into the tumor.Many pro-angiogenic
factors, including the most potent regulator and pivotal media-
tor VEGF, as well as FGF-2, PDGF, IGF2, TGFβ, and IL-8, are
all induced by hypoxia inducible factor 1 or 2, which are tran-
scription factors that bind to the hypoxia response element (HRE)
located in the promoters of these genes (Black et al., 2008; Wink
et al., 2011; Chowdhury et al., 2012).
Both hypoxia (<5% O2) and NO/RNS can stabilize HIF-1α
and HIF2α Both HIF-α subunits are constitutively transcribed
and translated, but immediately directed for degradation in nor-
moxia, through their hydroxylation of proline residues by the
prolyl hydroxylases (PHDs) that rely on oxygen as their substrate.
This hydroxylation recruits the von Hippel Lindau (VHL) pro-
tein, which has an E3 ubiquitin ligase activity that marks HIF-α
subunits for degradation in the proteasome. Hypoxia inactivates
PHDs due to the limited oxygen substrate, and therefore stabi-
lizes the HIF-α subunits, allowing their heterodimerization with
the HIF-1β subunit (Nizet and Johnson, 2009; Walmsley et al.,
2009; Rahat et al., 2011). Low levels of NO/RNS can also stabi-
lize HIF proteins by inactivating PHDs through oxidation of their
non-heme Fe+2-group, thereby causing reduced hydroxylation of
HIF-1α and its accumulation even in normoxic regions of the
tumor, close to the rims (Kimura et al., 2000, 2001).
Low amounts of NO further promote the induction of these
aforementioned pro-angiogenic genes by activating guanylate
cyclase and increasing cGMP levels, which help phosphorylate the
MAP kinases ERK1/2 and activate PI3K/Akt, that activate addi-
tional transcription factors that are needed for the induction of
the factors (Dulak and Jozkowicz, 2003; Ridnour et al., 2006).
Such pro-angiogenic factors directly affect endothelial cells, as
they are growth factors needed for their survival and prolifer-
ation, as well as for their spatial reorganization into tube-like
formation (Ridnour et al., 2006).
While helping to induce pro-angiogenic factors, NO/RNS sup-
press the expression of thrombospondin-1 (Tsp1) (Ridnour et al.,
2005), which limit angiogenesis by reducing the migration and
proliferation of endothelial cells. This cross-talk between NO and
Tsp1 is regulated by the concentrations of NO, as low NO lev-
els down-regulate Tsp-1 expression, and increased levels of Tsp-1
inhibit the pro-angiogenic effects of NO (Ridnour et al., 2006).
Low levels of NO/RNS can directly and indirectly via VEGF
enhance angiogenesis by activating MMP-1, MMP-9, and MMP-
13 (Ridnour et al., 2007; Ziche and Morbidelli, 2009), MMPs
are critical for angiogenesis, as they degrade components of the
ECM and pave the way for migration of endothelial cells into the
tumor, and of tumor cells out of the tumor to the nearest blood
vessel. High levels of MMPs, particularly MMP-9, release and
activate VEGF that is trapped by the ECM, and allow migration
of endothelial cells, as well as leukocytes and metastatic tumor
cells. In addition to its direct pro-angiogenic properties, VEGF is
also a regulator of MMP-9, thus creating a positive feedback loop
whereby MMP-9 and VEGF enhance each other (Hollborn et al.,
2007). Low levels of NO/RNS control MMPs by activating JNK
and NF-κB (Yang et al., 2011), and simultaneously down-regulate
MMP’s endogenous inhibitor TIMP-2 (Ziche and Morbidelli,
2009). Reduced levels of TIMP-2 not only allow the activity of
MMPs, but are also pro-angiogenic, independently of their effect
on MMPs (Lahat et al., 2011).
Thus, low NO/RNS levels enable multiple paths for angiogene-
sis, and shift the balance between pro- and anti-angiogenic factors
to enhance angiogenesis.
Immune evasion. NO/RNS further contribute to the inhibi-
tion of anti-tumor immune responses and the ability of tumors
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to evade the immune system by increasing T cell apopto-
sis, and by nitrating TCR on CD8+ T cells, thereby inhibit-
ing their ability to kill antigen-specific tumor cells (Ostrand-
Rosenberg and Sinha, 2009; Jia et al., 2010). A recent paper
now describes an additional role for tumor-produced NO/RNS
in attracting MDSCs and inducing their function (Jayaraman
et al., 2012), thus enhancing immunosuppression and helping
the tumors to evade immune recognition. This study further
illustrates the importance of the cell type producing NO/RNS,
and its critical role in mediating tumor cell-macrophage
interactions.
Thus, tumor cells have a vested interest to lower NO con-
centrations in the tumor microenvironment. They employ dif-
ferent strategies, including the secretion of immunosuppressive
cytokines (e.g., IL-10, TGFβ and PGE2), the use of the hypoxic
microenvironment that inactivate iNOS activity, and the deple-
tion of L-arginine by arginase-I, to reduce NO production in
the infiltrating macrophages. By doing so, tumor cells repro-
grammacrophages to ensure their pro-angiogenic activation, thus
“enslaving” them to the tumor needs.
REGULATION OF iNOS EXPRESSION AND NO ACTIVITY
The regulation of iNOS expression and its activity have been
extensively reviewed before (Alderton et al., 2001; Aktan, 2004;
Pautz et al., 2010) and we will only briefly describe it here. The
main regulatory checkpoint on iNOS expression is usually consid-
ered to be transcriptional. In mouse, stimulation by lipopolysac-
charide (LPS) or by one of the pro-inflammatory cytokines (e.g.,
IL-1β, TNFα, IFNγ) is sufficient to induce high amounts of iNOS,
whereas in human cells a mixture of several stimuli is needed to
achieve iNOS induction (Xie and Nathan, 1994). These species-
dependent differences were explained by the many differences
found between the human and mouse iNOS promoters (Xie and
Nathan, 1994; De Vera et al., 1996). The human promoter is
longer and more complex than the mouse promoter, and con-
sists of many binding sites for transcription factors that mediate
both enhancement and inhibition of iNOS transcription, such as
AP-1, C/EBPβ, EGFR-STAT3, HMGA1, p53, KLF6, five NF-κB
sites, Oct-1, two binding sites for IRF-1/STAT-1α, HIF-1, Tcf-
4, YY1 and many more (Taylor et al., 1998; Pautz et al., 2010).
Only some of these sites can be found in the mouse promoter,
which is shorter, and contains proximal and a distal regulatory
regions that include mostly NF-κB and IRF-1 binding sites that
mediate induction by LPS and IFNγ, respectively. Because of
these differences, it was suggested that iNOS effects in mouse
tumor models are different than in human tumors, as human
cells tend to express lower levels of iNOS and generate less NO
(Ambs and Glynn, 2011). However, high amounts of iNOS can be
expressed in human cells, provided that a sufficiently strong stim-
ulation is introduced consisting of a mixture of several cytokines
in vitro, or during inflammation in vivo (Xie and Nathan, 1994;
Albina, 1995). Furthermore, the hypoxic microenvironment in
the tumor dictates a reduced production of NO, regardless of the
high expression of the protein (Melillo et al., 1996; Daniliuc et al.,
2003). Thus, we maintain that NO concentrations in the tumor
are reduced in all species in correlation to the tumor size, indi-
cating that NO production in large, hypoxic tumors is reduced
while iNOS protein may be highly expressed in the tumor cells
and infiltrating macrophages (Perske et al., 2010). Therefore, the
role of iNOS protein expression as a prognostic indicator must be
re-examined.
The cytokine network that regulates tumor cell-macrophage
interactions is quite complex. In addition to the anti-
inflammatory microenvironment (e.g., TGFβ, IL-10, and PGE2)
that invokes immunosuppression and reprograms macrophage
toward M2 activation, pro-inflammatory cytokines (e.g. TNFα,
IL-1β and IFNγ) are also present, albeit in relatively low
concentrations. At such levels, these cytokines serve to induce
adhesion molecules, MMPs, VEGF, and even COX-2 and PGE2
production (Dinarello, 2006, 2010). Another microenvironmen-
tal factor is the presence of apoptotic cells that release many
factors, including shingosine-1-phosphate (S1P) that is taken up
by TAMs and repolarizes them toward M2 activation. M2 acti-
vated macrophages increase the expression of arginase-I, which
changes their iNOS/arginase-I ratio and reduces their ability to
produce NO/RNS (Weigert and Brune, 2008). A special role
was highlighted for CSF-1, which is secreted from tumor cells
and helps recruit macrophages and sustain them in the tumoral
microenvironment, and to EGF, which is secreted from the infil-
trating macrophages and serves to induce tumor cell migration
and invasion (Hernandez et al., 2009). In respect to iNOS reg-
ulation, these central mediators also affect its expression, as
macrophage EGF induces iNOS in tumor cells (Lo et al., 2005)
and tumor cell CSF-1 induces iNOS in macrophages (Lin et al.,
2010).
Another important checkpoint is the stability of the iNOS
mRNA, which is mediated primarily by the AU-rich ele-
ments (ARE) found in the 3′-UTR regions of the transcript.
Different RNA binding proteins compete for the binding to
the 3′-UTR of iNOS mRNA, including HuR which usually
stabilizes mRNAs and is increased upon cytokine induction,
and KSRP and tristetraprolin (TTP), which usually mediate
destabilization (Pautz et al., 2010). In murine cells, iNOS
mRNA degradation was enhanced by TGFβ, and was medi-
ated by the RNA binding proteins PTB (hnRNP I) and
hnRNP L (Pautz et al., 2010). Thus, the balance between these
proteins may mediate cell type-specific regulation of iNOS
expression.
Translation of iNOS protein may be inhibited by small,
non-coding RNA molecules known as microRNAs (miRNA).
However, there is no direct evidence for the binding of spe-
cific miRNAs to iNOS mRNA. One report mentions the indirect
translational inhibition of iNOS mRNA through the inhibition
of the suppressor of cytokine signal (SOCS-1) mRNA by miR-
155 (Wang et al., 2009), and we (Perske et al., 2010) and others
(Dai et al., 2008) have shown the involvement ofmiR-146 in iNOS
regulation.
Finally, the activity of the iNOS enzyme is also tightly regu-
lated. Since the enzyme requires L-arginine as its substrate, argi-
nine availability, transport or consumption may have profound
implications on iNOS activity. Likewise, mechanisms regulating
the availability of additional co-factors, like tetrahydrobiopterin
(BH4), also affect iNOS activity (Pautz et al., 2010). The activity
of iNOS demands that the protein is homodimerized to ensure
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correct electron transfer. Protein–protein interactions with addi-
tional proteins, such as NAP110 (Ratovitski et al., 1999b) and
kalirin (Ratovitski et al., 1999a) were shown to inhibit iNOS
activity, whereas other proteins, such as rac2 (Kuncewicz et al.,
2001) and α-acitinin-4 (Daniliuc et al., 2003) are required for
its activity. The latter two proteins ensure that iNOS is properly
localized at the cortical zone, just underneath the plasma mem-
brane, and similar to the other NOS isoforms, enable its activity at
this cellular compartment. Disruption of this interaction (e.g., by
hypoxia) displaces the enzyme back to the cytoplasm and renders
it inactive.
NO PRODUCTION BY TUMOR CELLS
Tumor cells, and not only macrophages, can induce iNOS expres-
sion and NO production. However, the potential biological rele-
vance of iNOS expression in different malignant human tumors is
still controversial, mostly because of technical reasons. Expression
of iNOS is often determined by immunohistochemistry, western
blot analysis or by real-time RT-PCR—all of which are basi-
cally semi-quantitative approaches. Most times, these techniques
are applied on paraffin-embedded archival specimens, but these
may produce unreliable results due to mRNA degradation in
the paraffin-embedded blocks, or due to the recently emerging
observations that iNOS protein expression does not necessar-
ily correspond to NO production. Moreover, different ways to
score iNOS immune reactivity (e.g., % of positive cells and/or
intensity of staining) make comparison of these studies difficult.
Measurement of the activity of the protein is thus restricted to
fresh tissues, using primarily the indirect Griess reaction to mea-
sure accumulation of nitrates and nitrites (Cianchi et al., 2004),
or the direct approach of measuring the conversion of L-[3H]-
arginine to L-[3H]-citrulline (Koh et al., 1999; Franchi et al.,
2006). Another indirect approach to indicate iNOS activity is
the immunohistochemical detection of nitrotyrosinated proteins
(Goto et al., 1999; Gochman et al., 2012) or 8-nitro-guanine DNA
adducts (Chaiyarit et al., 2005; Ma et al., 2006) that can also be
applied on paraffin embedded tumor specimens. However, these
indirect approaches do not quantify the extent of iNOS activity,
they may be influenced by high activity of other NOS isoforms
or by the generation of other RNS (e.g., hypochlorous acid and
nitrites that may also nitrotyrosinate proteins) (Radi, 2004), and
they are very difficult to compare due to the use of different
antibodies or different staining protocols.
Bearing in mind those difficulties, we have tried to critically
review the literature, asking whether iNOS expression is corre-
lated with tumoral grade and stage and with poor prognosis, and
whether it is limited to macrophages or to tumor cells in specific
types of cancer. Table 1 present the conflicting results of this com-
parison, and emphasizes how poorly understood the role of NO
in tumor biology remains.
In certain types of cancer (e.g., gastric cancer, melanoma)
increased iNOS expression is found to be associated with tumor
stage and grade or with tumor progression toward metastases, as
well as with poor prognosis. In contrast, in other types of can-
cer (e.g., ovarian cancer), iNOS expression is reduced with tumor
progression and with poor prognosis. Studies of some tumor
types (e.g., colorectal, breast, brain, lung, and cervical cancers)
are controversial, indicating either increased or reduced iNOS
expression as tumor progresses, whereas in yet other types of
cancer (e.g., bladder carcinoma, pancreatic, cervical cancers) pos-
itive and even strong iNOS expression was not correlated with
either grade/stage or with prognosis. However, in all the stud-
ies we found (Table 1), moderate or strong expression of iNOS
could be detected in the immunohistochemical images within
stromal or inflammatory infiltrating cells, which in some studies
were even identified as macrophages. Macrophage iNOS expres-
sion, however, was not correlated with prognosis, survival rates,
invasiveness or tumor recurrence after therapy.
Evidently, these conflicting results reflect our lack of under-
standing of the many roles NO plays within the tumor, so
that we can only speculate on what may be happening. These
results might indicate a different role for iNOS expression in
macrophages vs. tumor cells. Macrophages in the tumor stroma
exhibit strong iNOS expression regardless of tumor grade and
stage, and may produce high levels of NO/RNS that are gradu-
ally diminished as they infiltrate the hypoxic core of the tumor.
The same is probably true for the tumor cells, and we can
assume that tumor cells that are close to the hypoxic core produce
less NO/RNS. Thus, the ability of the tumor microenviron-
ment to uncouple iNOS expression and NO production (e.g.,
via hypoxia) may result in a gradient of NO/RNS concentra-
tions and make it very difficult to assess their true levels within
the tumor. The few studies (Table 1) that showed accumulation
of nitrotyrosinylated proteins and interpreted these as a mea-
sure of increased NO/RNS production are not necessarily right,
as protein nitrotyrosinylation is an irreversible reaction that may
accumulate over time as the tumor progresses. It is possible that
generation of high NO/RNS levels induce genetic instability, not
only during the early stages of tumor development, but also as
an on-going process, which helps tumor cells accumulate more
mutations and further advance to the next malignant stage. It is
equally possible that despite the high expression of iNOS pro-
tein, the enzyme is rendered inactive, and produces low amounts
of NO/RNS that are pro-angiogenic and contribute to tumor
aggressiveness. Thus, it is highly important to develop new tech-
niques that will allow to precisely determine NO/RNS concen-
trations within tumors, preferably in paraffin-embedded archival
specimens.
Finally, the fact that such conflicting data are observed in
certain cancer types, whereas other cancer types reveal a more
consistent behavior, may suggest that other, yet unidentified fac-
tors, are involved in the regulation of iNOS activity. Such factors
may include components of the specific tissue (e.g., ECM pro-
teins, interstitial cells), or the tumor cells themselves. The fact
that macrophages express iNOS in all types of tumors may sug-
gest that tumor cells differently regulate their iNOS expression
and NO production.
TUMOR CELL PRODUCTION OF NO—FUTURE PERSPECTIVES
High levels of NO are strongly associated with initiation of apop-
tosis, and therefore, it seems reasonable to try and manipulate
tumor cells to maintain high levels of NO/RNS concentrations as
means of therapeutic intervention. In fact, early studies demon-
strated that manipulating tumor cells to produce high NO/RNS
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Table 1 | Patterns of iNOS expression and NO production in tumor cells, as influenced by tumor grade and stage.
Tumor type Prognosis/survival iNOS activity Expression of iNOS in
infiltrating immune cells
References
EXPRESSION OF INOS INVERSELY CORRELATES WITH TUMOR GRADE AND STAGE OR WITH METASTASES
Ovarian cancer No effect on prognosis;
Low iNOS expression correlates
with poor prognosis
N/Aa;
Low intra-cystic NO
levels in advanced
grade
N/Mb;
Strong iNOS staining in
macrophages or
mononuclear cells
Klimp et al., 2001; Ozel
et al., 2006; Anttila et al.,
2007; Nomelini et al., 2008
Colorectal cancer N/M; Low iNOS expression
correlates with low survival
N/A; Reduced in tumors
relative to normal tissue
Strong staining in
mononuclear cells
Moochhala et al., 1996;
Ropponen et al., 2000; Hao
et al., 2001; Ohta et al., 2006
Breast cancer N/M N/A Strong iNOS staining of
macrophages only in grade
III tumors
Tschugguel et al., 1999
Brain cancer No effect N/A Some stromal staining of
iNOS
Giannopoulou et al., 2006
Lung cancer (NSCLC) High iNOS expression predicts
better survival
N/A Strong iNOS staining in
alveolar macrophages
Puhakka et al., 2003
Cervical cancer N/M; High iNOS expression
correlates with favorable prognosis,
low risk for recurrence
N/A N/M; Some expression in
inflammatory infiltrate
Mazibrada et al., 2008;
Eggen et al., 2011
EXPRESSION OF INOS DIRECTLY CORRELATES WITH TUMOR PROGRESSION, GRADE/STAGE, OR METASTASES
Malignant melanoma High iNOS expression is associated
with invasiveness, metastases, and
increased risk for death. No
expression in melanocytic naevi
N/A N/M, Intense staining of
macrophages as tumor
progresses
Massi et al., 2001;
Ekmekcioglu et al., 2006
Colorectal cancer N/M; High iNOS expression
associated with poor survival
N/A; Increased
nitrotyrosine staining
Expression of iNOS in few
inflammatory mononuclear
cells
Zafirellis et al., 2010;
Gochman et al., 2012
Breast cancer No prognostic effect; Strong iNOS
associated with poor prognosis in
ER-negative patients or with lower
disease-free survival rates
N/A Strong iNOS staining of
stromal cells; No iNOS
staining in stromal cells
Vakkala et al., 2000; Bulut
et al., 2005; Glynn et al.,
2010
Brain cancer No prognostic effect N/A N/M Hara and Okayasu, 2004
Lung cancer (NSCLC) High expression relative to no-tumor
tissues
Elevated in tumors
(Griess)
Few stromal cells may be
stained
Lee et al., 2003
Cervical cancer High iNOS expression is associated
with decreased survival and
metastases
N/A N/M Chen et al., 2005
Gastric cancer High iNOS expression, especially
when accompanied by COX-2
staining, is associated with poor
prognosis, invasiveness and/or
metastasis
N/A; Increased
nitrotyrosine staining
N/M; Weak to moderate
positive staining in stromal
mononuclear cells
Rajnakova et al., 2001; Feng
et al., 2002; Li and Xu, 2005;
Chen et al., 2006; Zhang
et al., 2011
Head and neck (HNSCC) N/M; High iNOS expression
correlates with metastases and poor
prognosis or increased 5-year
recurrence rate
N/A; Elevated in
carcinoma
Positive iNOS staining in
inflammatory cells, probably
macrophages
Chen et al., 2002; Franchi
et al., 2002; Zhang et al.,
2005; Ou Yang et al., 2011
Oral cancer Expression of iNOS correlated with
metastasis
N/A Positive iNOS staining in
stroma cells, probably
macrophages
Chen et al., 2002
Pancreatic cancer High iNOS expression is associated
with lymph node metastases
N/A N/A Kasper et al., 2004
NO CORRELATION TO TUMOR GRADE AND STAGE/NOT CONCLUSIVE
Cervical cancer No effect N/A N/M; Some positive stromal
cell
Oka et al., 2003
(Continued)
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Table 1 | Continued
Tumor type Prognosis/survival iNOS activity Expression of iNOS in
infiltrating immune cells
References
Head and neck (HNSCC) No prognostic effect; iNOS
expression is not associated with
tumor grade; iNOS activity is
associated with lymph node
metastasis
N/A; Elevated in tumor
periphery
Occasional staining of
mononuclear cells; positive
staining of macrophages
Pukkila et al., 2002;
Jayasurya et al., 2003;
Franchi et al., 2006
Bladder cancer Strong iNOS staining in all bladder
tissue, regardless of stage and
grade
N/A; No change or
elevated nitrites in
urine samples from
TCC relative to controls
N/M; Strong staining in
inflammatory cells
(macrophages and
neutrophils)
Swana et al., 1999; Eijan
et al., 2002; Lin et al., 2003;
Sandes et al., 2005
Pancreatic cancer No prognostic effect N/A N/M; iNOS positive stroma
cells
Vickers et al., 1999; Kong
et al., 2002
aN/A, not assayed.
bN/M, not mentioned.
inhibited tumor growth. For example, orthotopically implant-
ing pancreatic tumor cell lines that expressed different levels of
iNOS showed that tumor cells with low iNOS expression devel-
oped pancreatic tumors with metastases to the liver and formed
ascites, while tumor cells with high level of iNOS expression
did not develop tumors (Wang et al., 2003). In other studies,
transfection of tumor cells with the iNOS gene using adenovi-
ral or retroviral vectors lead to their ability to produce NO
and other pro-angiogenic proteins, but these cells did not form
tumors in nude mice due to initiation of apoptosis (Le et al.,
2005) or developed small tumors with no lung metastases in
comparison to non-transfected cells (Juang et al., 1998). These
studies highlighted the importance of tumor cell iNOS expres-
sion, but did not take into account the effects of the infiltrating
macrophages or the changing microenvironment. Furthermore,
since iNOS was continuously overexpressed in the tumor cells,
it is likely that their apoptotic death occurred at an early stage
of tumor development, before macrophages were recruited and
“re-educated” to become pro-angiogenic and immunosuppres-
sive. Moreover, such a manipulation of tumor cells that involves
their transfection with an iNOS construct designed to cause high
iNOS expression is clearly not easily feasible in the clinical real-
life scenario, where tumors are often diagnosed after they have
gained considerable mass and created an immunosuppressive
microenvironment.
A different approach to treat tumors with NO/RNS was to
use macrophages. Macrophages were isolated from a patient,
activated ex vivo as M1 macrophages, and then re-introduced
back to the same patient. Three qualities make this autologous
macrophage adoptive transfer an appealing approach: (1) their
tumoricidial abilities that is based on production of high con-
centration of cytotoxic molecules such as NO/RNS; (2) the ease
to isolate them from patients in large numbers and to activate
them ex vivo before their re-infusion; (3) their ability to home
directly to the tumor, thereby specifically targeting the tumor cells
(Murdoch et al., 2004; Allavena et al., 2008).
However, previous experiments performed on human sub-
jects, where monocytes were collected, classically stimulated
ex vivo with IFNγ and/or LPS, and autologously re-infused
into the patient, proved that although the process was safe
with only minor side effects, no significant beneficial clinical
effects were observed (Andreesen et al., 1998; Hennemann et al.,
1998). Another study showed that autologous IFNγ-activated
macrophages that were intrapleurally injected into patients suf-
fering from malignant mesothelioma showed only limited and
insignificant (about 14%) anti-tumor response (Monnet et al.,
2002), although these macrophages produced high levels of TNFα
and NO/RNS and proved to be cytotoxic to tumor cells in vitro.
In mice, such treatment resulted in inhibition of metastasis for-
mation, with sometimes attenuated growth, but no regression
of the primary tumor (Andreesen et al., 1998; Perske et al.,
2010). Adoptive transfer of activated macrophages that were
first transduced with macrophage colony stimulating factor (M-
CSF) and IFNγ by recombinant adenovirus infection and were
tumor-pulsed prior to their re-infusion, succeeded in reduc-
ing pulmonary metastases in a B16F10 melanoma model. These
gene-modulated macrophages exhibited increased secretion of
cytotoxic molecules, including NO, and increased antigen presen-
tation when pulsed with tumor lysates, suggesting that on-going
activation of macrophages in vivo is critical to their anti-tumor
effects and to their ability to recruit specific cytotoxic T cells
(Lei et al., 2000). However, such an approach, which demands
isolation of macrophages in large amounts followed by their
gene-modulation in combination with isolation of enough tumor
tissue to produce lysates for macrophage pulsing, seems very
elaborate and difficult to achieve in humans.
In retrospect, the macrophage therapy approach probably
failed to take into account the ability of the hypoxic and immuno-
suppressive microenvironment to skew the ex vivo M1-activated
macrophages back toward an M2 mode of activation, which
resulted in failure of these trials. The tumor microenvironment,
which is rich in anti-inflammatory mediators (e.g., TGFβ, IL-10,
PGE2) and with apoptotic cell debris, directly neutralizes such
pre-treated M1-activated macrophages (Kees and Egeblad, 2011).
Specifically, even if such macrophages expressed high levels of
the iNOS protein, the hypoxic microenvironment would inhibit
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their production of high amounts of NO/RNS. Additionally,
macrophage therapy approach failed to provide on-going signals
that would maintain the anti-tumoral phenotype of the infused
macrophages.
How can we, then, manipulate tumor cell-macrophage inter-
actions in order to eradicate the tumor? It is still advisable to
use macrophages, but only as long as we can maintain their skew
toward M1 activation. It is possible that after surgery, radio- or
chemotherapy, when the tumor mass is reduced, regulatory cells
(e.g., Treg orMDSCs) are diminished, and the microenvironment
is less hypoxic and immunosuppressive, thus generating a small
window of opportunity for a more successful macrophage ther-
apy. Indeed, attempts to combine such therapies and activate the
innate immune cells in a timely manner are now beginning to be
explored (Kees and Egeblad, 2011).
We can also use NO as a radio- or chemo-sensitizer to enhance
the beneficial effects or radio- and chemotherapy. It has been
shown that well-oxygenated tumor cells that reside near blood
vessels or at the tumor rim are radiosensitive, whereas those that
are located in hypoxic areas may be 3-times more radio-resistant.
Irradiation kills proliferating tumor cells through accumulation
of DNA damage that is dependent on presence of oxygen and the
free radicals it generates. Hypoxia is believed to increase radio-
resistance through the accumulation of HIF-1, which in turn,
down-regulates pro-apoptotic genes, enhances multidrug resis-
tant proteins and induces expression of genes like VEGF and
enzymes of the glycolytic pathway, thus ensuring blood supply
and energy required for tumor cell survival and proliferation
(Fitzpatrick et al., 2008; Yasuda, 2008). The potential use of
NO as a radio- and chemo-sensitizer for such resistant tumor
cells is currently being explored, and several mechanisms could
explain its effects. By binding to cytochrome c oxidase, NO can
inhibit mitochondrial respiration and generate ROS that activate
PHDs and HIF-1 hydroxylation, leading to increased degrada-
tion of HIF-1 in hypoxia (Fitzpatrick et al., 2008; Yasuda, 2008).
Inhibition of the mitochondria also diverts oxygen from this
organelle to the cytoplasm, thus protecting cells from death.
Much like oxygen, NO can directly damage DNA, lipids and
proteins (probably though generation of peroxynitrite), and sys-
temically NO has a vasodilative effect that provides more blood
supply to the tumor cells and maintain their oxygenation. Thus,
NO or NO-donors have been explored as potential adjuvants for
radiotherapy. However, results remain controversial, and studies
show both beneficial and detrimental effects, depending on the
tumor microenvironment, NO concentrations, the oxygenated
state of the tumor, systemic responses and more (Oronsky et al.,
2012). Use of NO-donors to radio-sensitize tumor cells may also
cause serious systemic side effects, such as hypotension, which
may result in further increasing tumor hypoxia and tumor cell
radio-resistance, and the use of IFNγ administration to induce
iNOS expression is limited because of its toxicity and vascular
effects (Fitzpatrick et al., 2008). However, this highlights again the
importance of endogenous NO production by the tumor cells.
NO/RNS production plays a key role in tumor cell-
macrophage interactions, as both cell types can produce it.
Table 1 demonstrates that in some tumor types, high grade
tumors or metastatic tumor cells tend to reduce their iNOS
protein expression or lose it completely, as a means of escap-
ing the immune system. We have previously shown in a murine
renal cell carcinoma (RENCA) model injected subcutaneously,
that even high concentrations of NO/RNS within the tumor
in vivo, whether delivered by an NO donor (NOC-18) or by M1-
activated macrophages, could only attenuate tumor growth, but
did not regress the tumor (Perske et al., 2010). Furthermore,
in vitro co-culture of RENCA tumor cells that did not express
iNOS with RAW 264.7 macrophages, in the presence of IFNγ
and LPS that strongly induced macrophage iNOS expression,
did not result in tumor cell death. Only when these tumor cells
were induced to express iNOS, even in low levels, by alleviating
the translational inhibition on the protein through neutraliza-
tion of microRNA-146a (miR-146a), macrophage-induced tumor
cell death was initiated (Perske et al., 2010). Thus, high exoge-
nous concentrations of NO/RNS in the tumor microenvironment
are not sufficient to kill tumor cells, and the decision whether
tumor cells will undergo apoptosis depends on their own ability
to produce NO. Other studies that demonstrated the importance
of endogenous tumor cell NO production to their susceptibil-
ity to apoptosis support our findings (Le et al., 2005). Different
tumor cells were transfected with wild type or mutant iNOS con-
structs that resulted in different degrees of iNOS activity, and
then implanted s.c. into nude mice. NO production in the wild
type cells strongly suppressed tumor cell proliferation and tumor
growth by inducing their apoptosis in a concentration-dependent
way, whereas induction of the expression of pro-angiogenic fac-
tors, such as VEGF and IL-8 remained constant (Le et al., 2005).
These findings and our own, highlight one strategy that tumor
cells may take to evade macrophage-induced death by reducing
or abrogating their iNOS expression. It is possible that miRNA-
146a affects additional targets besides iNOS, and thus acts as a
general stimulator, this time of the tumor cells rather than the
macrophages. These findings also highlight the importance of the
dialogue between tumor cells and macrophages, and underscore
the degree of control that tumor cells exert over their environment
and the functioning of infiltrating cells.
This current understanding of the important translational
regulation of iNOS expression through miRNA-146a, that
allows tumor cells to evade macrophage-induced death, may be
expanded to envision new therapeutic approaches that are based
on the ability to manipulate NO production in the tumor cells.
To do this, we must first better understand the precise machin-
ery that allows miR-146a to inhibit iNOS translation, and then
find an efficient delivery system of anti-miR-146a specifically into
tumor cells, so we can manipulate iNOS production in these
cells. Such manipulation of iNOS expression in tumor cells, com-
bined with infusion of ex vivo M1-activated macrophages could
become an attractive therapeutic approach, which overrides both
the immunosuppressive effects of the microenvironment and the
evasion strategy of tumor cells.
In conclusion, it is the overall concentrations of NO/RNS,
rather than the extent of iNOS expression, that ultimately
determine their activities. Low levels of NO/RNS are pro-
angiogenic and support immune evasion, whereas high amounts
trigger apoptosis. Thus, our goal is to increase NO/RNS pro-
duction in both tumor cells and macrophages, by overcoming
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their respective inhibitory mechanisms, so that the pro-
angiogenic effects of NO/RNS are inhibited, the immune system
regains recognition of the tumor cells and its pro-apoptotic effects
are enhanced to effectively eradicate the tumor.
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